Table 2.
Predictive factors for NAb production in patients as assessed in multivariate and univariate analysis.
| Variables | Univariate (OR, 95% CI) | Multivariate * (OR, 95% CI) | p-Value |
|---|---|---|---|
| Age | 0.99, 0.97–1 | - | |
| Gender Male Female |
(Reference) 1.34, 0.8–2.2 |
- | |
| Body Mass Index | 1.03, 0.95–1.1 | - | |
| Lymphopenia | 0.96, 0.35–2.6 | - | |
| Immunoparesis (decreased g-globulins) | 0.56, 0.04–7.44 | - | |
| Symptomatic disease | 0.34, 0.3–3.9 | - | |
| Disease type | |||
| Non-Hodgkin lymphoma | (Reference) | (Reference) | |
| Hodgkin lymphoma | 4.7, 1.4–15.6 | 4.9, 1.3–18.4 | p = 0.019 |
| Chronic lymphocytic leukemia | 1.06, 0.46–2.4 | 0.96, 0.4–2.5 | |
| Active treatment | 0.14, 0.06–0.35 | 0.15, 0.05–0.42 | p < 0.001 |
| Rituximab in the last 12 months | 0.27, 0.1–0.7 | 0.33, 0.1–1.1 | p = 0.07 |
| Treatment type No treatment Bruton’s tyrosine kinase inhibitors (BTKi) Rituximab Combination (BTKi-Rituximab) Chemotherapy |
(Reference) 0.54, 0.2–1.5 0.2, 0.06–0.8 1, 0.8–1.2 1.24, 0.26–5.9 |
- |
Categorical variables: gender, symptomatic disease, disease type, active treatment, rituximab in the last 12 months, treatment type; * only statistically significant variables in the univariate analysis were included in the multivariate model.